ArticleJournal of translational medicine2025
Liver ischemia-reperfusion promotes tumor metastasis via neutrophil-endothelial interactions: targeting ICAM1 to prevent metastatic recurrence.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundLiver ischemia-reperfusion (IR) injury, commonly encountered in liver surgery and transplantation, has been linked to enhanced metastatic potential in hepatic tumors. The mechanisms underlying this process, however, remain poorly understood.
methodsIn this study, we utilized mouse models of hepatocellular carcinoma (HCC) and colorectal cancer (CRC) to investigate the role of liver IR in tumor metastasis. We employed ICAM1 blockade with atorvastatin to assess its impact on tumor progression. The effects of neutrophil depletion and ICAM1 inhibition on tumor metastasis were evaluated through in vivo and in vitro assays, while clinical data from HCC patients were analyzed for correlations with ICAM1 expression and prognosis.
resultsOur results demonstrate that liver IR significantly increases liver and lung metastasis, decreases survival, and facilitates tumor cell infiltration through neutrophil-mediated interactions. ICAM1 expression was upregulated in liver endothelial cells following IR, promoting neutrophil adhesion and tumor cell transmigration. Atorvastatin treatment reduced ICAM1 expression, attenuated neutrophil recruitment, and inhibited tumor metastasis in both liver and lung. Clinical analysis showed that high ICAM1 expression in HCC tissues was associated with poor prognosis, increased neutrophil infiltration, and worse overall survival (OS) and recurrence-free survival (RFS).
conclusionsThis study uncovers the critical role of the ICAM1-neutrophil axis in mediating liver IR-induced metastasis. Targeting ICAM1, particularly with atorvastatin, presents a promising therapeutic strategy to prevent metastatic recurrence in liver surgery patients and improve clinical outcomes in HCC.
trial registrationThis study is a retrospective observational analysis of clinical data from HCC patients, with no prospective assignment of interventions by the investigators. As per ICMJE guidelines, clinical trial registration is not required for purely observational studies where intervention assignment is not at the discretion of the investigator.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.